查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1700110

2032 年骨质疏鬆症药物市场预测：按药物类别、给药途径、分销管道、最终用户和地区进行的全球分析

Osteoporosis Drugs Market Forecasts to 2032 - Global Analysis by Drug Class (Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), Calcitonin and Other Drug Classes), Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球骨质疏鬆症药物市场预计在 2025 年达到 163 亿美元，到 2032 年将达到 238 亿美元，预测期内的复合年增长率为 5.5%。

骨质疏鬆症药物是用来预防、治疗和控制骨质疏鬆症的药物。骨质疏鬆症药物透过减缓骨质流失（抗吸收药物）或促进骨形成（合成代谢药物）发挥作用。常见的选择包括双磷酸盐、选择性雌激素受体调节(SERM)、抑钙素、副甲状腺素类似物和单株抗体。这些药物有助于降低骨折风险、提高骨骼密度和维持骨骼强度。骨质疏鬆症药物是根据年龄、性别、骨折史和骨骼密度等因素开出的，通常与钙、维生素 D 和生活方式的改变结合使用，以达到最佳骨骼健康和预防骨折。

老年人口不断增加

老年人口的增加是骨质疏鬆症药物市场成长的主要驱动力。随着老龄化的增长，骨骼密度会降低，骨质疏鬆症的可能性也会增加，因此对有效治疗的需求也越来越大。随着老年人获得医疗保健的机会和对医疗保健的了解不断增加，市场正在不断扩大。此外，改良的药物配方和客製化的治疗方法可以满足老年人的特殊需求。随着政府和医疗保健提供者越来越重视骨骼健康，预计市场将稳步扩大，这将为患者和製药公司带来利益。

骨质疏鬆症药物高成本

骨质疏鬆症药物的高价格限制了患者获得治疗的机会和坚持治疗，严重阻碍了市场的成长。许多患者，尤其是中低收入地区的患者，承受经济负担，导致需求减少，疾病负担增加。此外，高价格对医疗预算和保险系统造成压力，阻碍了其广泛采用。这些经济障碍限制了市场扩张，减缓了创新的采用，并迫使患者寻求替代或效果较差的治疗方法。

药物研发进展

随着疗效和安全性提高的创新治疗方法的推出，药物开发的进步极大地推动了骨质疏鬆症药物市场的发展。生物製药、单株抗体和新型疗法的突破性进展正在改善患者的治疗效果、降低骨折风险并提高骨骼密度。标靶治疗和个人化医疗的前沿研究正在扩大市场潜力。此外，下一代骨质疏鬆症药物的监管核准和研发投入的增加正在加速市场成长，为全球数百万骨质疏鬆症患者带来新的希望。

副作用和安全问题

副作用和安全问题是骨质疏鬆症药物市场成长的主要障碍。胃肠不适、心血管风险和非典型骨折等副作用会妨碍患者的依从性和医生的处方。安全警告和监管审查可能会进一步限制药物的采用并影响销售。负面宣传和诉讼也会削弱消费者信心。这些挑战推动了对替代疗法的需求，限制了市场扩张并影响了製药公司的收益来源。

COVID-19的影响：

由于医疗机构关闭和患者就诊次数减少，COVID-19 疫情导致诊断和治疗延迟，扰乱了骨质疏鬆症药物市场。供应链中断影响了药品的可得性，经济的不确定性限制了病患的负担能力。然而，远端医疗的兴起和停工期间人们对骨骼健康的认识的提高帮助市场復苏。疫情过后，随着医疗服务的恢復，市场復苏，骨质疏鬆症治疗的需求增加。

预计预测期内副甲状腺素(PTH) 类似物部分将占最大份额。

副甲状腺素(PTH) 类似物预计将在预测期内占据最大的市场占有率，因为它具有减缓骨质流失和促进骨形成的能力。这些药物，如特立帕肽和阿巴洛帕肽，对骨折风险高的患者特别有益，可以增加骨骼密度并降低骨折风险。意识的增强、骨质疏鬆症盛行率的上升以及有利的报销政策进一步推动了需求。此外，药物输送系统的持续研发努力和技术进步正在提升市场占有率。

预计在预测期内，医院部门的复合年增长率最高。

预计医院部门在预测期内将出现最高的成长率。这是因为医院提供骨骼密度扫描等先进的诊断工具，以促进早期发现和个人化治疗计划。此外，专业医疗保健专业人员加强病患教育和药物依从性以改善治疗效果。骨质疏鬆症盛行率的不断上升，加上医院提供全面照护的能力不断下降，导致药物需求不断增加。此外，与製药公司的合作支持研究和创新，进一步促进市场成长。

占比最大的地区：

在预测期内，由于配方的进步，预计北美将占据最大的市场占有率。意识的提高、政府的措施以及医疗保健服务的改善将进一步推动市场扩张。製药公司正在利用生技药品和合成代谢疗法进行创新，以改善患者的治疗效果。该市场透过降低骨折风险和提高生活品质对公众健康产生了积极影响。透过持续的研究发展和策略合作，该领域推动医学进步，为患者和医疗保健系统带来长期利益。

复合年增长率最高的地区：

在预测期内，由于医疗保健投资的增加，预计亚太地区将呈现最高的复合年增长率。政府和医疗保健提供者将骨质疏鬆症管理放在首位，从而增加了获得先进治疗的机会。药物配方的创新和生技药品的采用正在改善患者的治疗效果。此外，生活方式的改变和都市化也增加了骨质疏鬆症的盛行率，进一步推动了需求。扩大这些市场将刺激全部区域的经济成长、创造就业机会和製药研究的进步。

免费客製化服务：

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球骨质疏鬆症药物市场（依药物类别）

  • 双磷酸盐
    • 阿崙膦酸钠
    • 利塞膦酸盐
  • 选择性雌激素受体调节（SERM）
  • 副甲状腺素相关蛋白（PTHrP）类似物
  • 副甲状腺素（PTH）类似物
  • RANK配体（RANKL）抑制剂
  • 抑钙素
  • 其他药物类别

6. 全球骨质疏鬆症药物市场（依给药途径）

  • 口服
  • 注射

7. 全球骨质疏鬆症药物市场（按分销管道）

  • 医院药房
  • 零售药局
  • 网路药局

第八章全球骨质疏鬆症药物市场（按最终用户）

  • 医院
  • 诊所
  • 居家照护

9. 全球骨质疏鬆症药物市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Radius Health, Inc.
  • UCB SA
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd
  • Cipla Inc.
  • Daiichi Sankyo Company
  • Novo Nordisk A/S
  • Sun Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Bayer AG
  • Johnson & Johnson Services Inc.
  • Sanofi
  • Bristol-Myers Squibb Company
Product Code: SMRC29013

According to Stratistics MRC, the Global Osteoporosis Drugs Market is accounted for $16.3 billion in 2025 and is expected to reach $23.8 billion by 2032 growing at a CAGR of 5.5% during the forecast period. Osteoporosis drugs are medications designed to prevent, treat, or manage osteoporosis, a condition that weakens bones, making them fragile and prone to fractures. These drugs work by either slowing bone loss (anti-resorptive drugs) or promoting bone formation (anabolic drugs). Common classes include bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, parathyroid hormone analogs, and monoclonal antibodies. They help reduce fracture risk, improve bone density, and maintain skeletal strength. Prescribed based on factors like age, gender, fracture history, and bone mineral density, osteoporosis drugs are often combined with calcium, vitamin D, and lifestyle changes for optimal bone health and fracture prevention.

Market Dynamics:

Driver:

Rising Geriatric Population

The growing elderly population is a major driver of growth in the osteoporosis medicine market. There is a growing need for efficient treatments as osteoporosis becomes more likely as people age because of a decrease in bone density. The market is growing as a result of older individuals' increased access to and understanding of healthcare. Furthermore, improvements in medication formulations and customized therapies address the unique requirements of senior citizens. The market is expected to increase steadily as governments and healthcare providers place a greater emphasis on bone health, which will benefit patients as well as pharmaceutical businesses.

Restraint:

High Cost of Osteoporosis Drugs

The high cost of osteoporosis drugs significantly hampers market growth by limiting patient access and adherence to treatment. Many individuals, especially in low- and middle-income regions, struggle with affordability, leading to lower demand and increased disease burden. Additionally, high prices strain healthcare budgets and insurance systems, discouraging widespread adoption. This financial barrier restricts market expansion, slows innovation uptake, and forces patients to seek alternative or less effective treatment options.

Opportunity:

Advancements in Drug Development

Advancements in drug development are significantly driving the osteoporosis drugs market by introducing innovative therapies with improved efficacy and safety. Breakthroughs in biologics, monoclonal antibodies, and novel drug formulations are enhancing patient outcomes, reducing fracture risks, and improving bone density. Cutting-edge research in targeted treatments and personalized medicine is expanding the market potential. Additionally, regulatory approvals for next-generation osteoporosis drugs and increased R&D investments are accelerating market growth, offering new hope for millions suffering from osteoporosis worldwide.

Threat:

Side Effects & Safety Concerns

Side effects and safety concerns significantly hinder the growth of the osteoporosis drugs market. Adverse effects such as gastrointestinal issues, cardiovascular risks, and atypical fractures deter patient compliance and physician prescriptions. Safety warnings and regulatory scrutiny further limit drug adoption, impacting sales. Negative publicity and lawsuits also erode consumer trust. These challenges drive demand for alternative treatments, restricting market expansion and affecting pharmaceutical companies' revenue streams.

Covid-19 Impact:

The COVID-19 pandemic disrupted the osteoporosis drugs market by delaying diagnosis and treatment due to healthcare facility closures and reduced patient visits. Supply chain disruptions affected drug availability, while economic uncertainties limited patient affordability. However, increased telemedicine adoption and awareness of bone health during lockdowns supported market recovery. Post-pandemic, the market rebounded as healthcare services resumed, driving demand for osteoporosis treatments.

The parathyroid hormone (PTH) analogs segment is expected to be the largest during the forecast period

The parathyroid hormone (PTH) analogs segment is expected to account for the largest market share during the forecast period due to its ability to stimulate bone formation rather than just slowing bone loss. These drugs, such as teriparatide and abaloparatide, are particularly beneficial for high-risk fracture patients, enhancing bone density and reducing fracture risk. Increased awareness, rising osteoporosis prevalence, and favorable reimbursement policies are further boosting demand. Additionally, ongoing R&D efforts and technological advancements in drug delivery systems are expanding the market presence.

The hospitals segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals segment is predicted to witness the highest growth rate as hospitals provide advanced diagnostic tools like bone density scans, facilitating early detection and personalized treatment plans. Additionally, specialized healthcare professionals enhance patient education and medication compliance, improving outcomes. The increasing prevalence of osteoporosis, coupled with hospitals' ability to offer comprehensive care, fosters higher drug demand. Moreover, collaborations with pharmaceutical companies support research and innovation, further expanding market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to advancements in drug formulations. Increased awareness, government initiatives, and improved healthcare access further propel market expansion. Pharmaceutical companies are innovating with biologics and anabolic treatments, enhancing patient outcomes. The market positively impacts public health by reducing fracture risks and improving quality of life. With continuous R&D and strategic collaborations, the sector fosters medical advancements, ensuring long-term benefits for patients and healthcare systems.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR due to increasing healthcare investments. Governments and healthcare providers are prioritizing osteoporosis management, leading to improved accessibility to advanced treatments. Innovation in drug formulations and the adoption of biologics are enhancing patient outcomes. Additionally, lifestyle changes and urbanization are increasing the prevalence of osteoporosis, further propelling demand. This market expansion fosters economic growth, job creation, and advancements in pharmaceutical research across the region.

Key players in the market

Some of the key players in Osteoporosis Drugs Market include Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Radius Health, Inc., UCB S.A., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Cipla Inc., Daiichi Sankyo Company, Novo Nordisk A/S, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Bayer AG, Johnson & Johnson Services Inc., Sanofi and Bristol-Myers Squibb Company.

Key Developments:

In March 2025, Taiwan-based Formosa Pharmaceuticals announced an exclusive licensing agreement with Cipla Limited referred to as "Cipla" for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007).

In February 2025, Summit Therapeutics Inc. announced a clinical trial collaboration with Pfizer Inc. to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.

In February 2025, Alloy Therapeutics Inc. announced its latest strategic collaboration with Pfizer Inc., to develop a new platform that could enhance Pfizer's ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery technologies.

Drug Classes Covered:

  • Bisphosphonates
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analogues
  • Parathyroid Hormone (PTH) Analogs
  • RANK Ligand (RANKL) Inhibitors
  • Calcitonin
  • Other Drug Classes

Routes of Administration Covered:

  • Oral
  • Injectable

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Hospitals
  • Clinics
  • Homecare Settings

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Osteoporosis Drugs Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Bisphosphonates
    • 5.2.1 Alendronate
    • 5.2.2 Risedronate
  • 5.3 Selective Estrogen Receptor Modulators (SERMs)
  • 5.4 Parathyroid Hormone-Related Protein (PTHrP) Analogues
  • 5.5 Parathyroid Hormone (PTH) Analogs
  • 5.6 RANK Ligand (RANKL) Inhibitors
  • 5.7 Calcitonin
  • 5.8 Other Drug Classes

6 Global Osteoporosis Drugs Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Injectable

7 Global Osteoporosis Drugs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies

8 Global Osteoporosis Drugs Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Homecare Settings

9 Global Osteoporosis Drugs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Amgen Inc.
  • 11.2 Eli Lilly and Company
  • 11.3 Merck & Co., Inc.
  • 11.4 Novartis AG
  • 11.5 Pfizer Inc.
  • 11.6 GlaxoSmithKline plc
  • 11.7 Radius Health, Inc.
  • 11.8 UCB S.A.
  • 11.9 Teva Pharmaceutical Industries Ltd.
  • 11.10 F. Hoffmann-La Roche Ltd
  • 11.11 Cipla Inc.
  • 11.12 Daiichi Sankyo Company
  • 11.13 Novo Nordisk A/S
  • 11.14 Sun Pharmaceutical Industries Ltd.
  • 11.15 AbbVie Inc.
  • 11.16 Bayer AG
  • 11.17 Johnson & Johnson Services Inc.
  • 11.18 Sanofi
  • 11.19 Bristol-Myers Squibb Company

List of Tables

  • Table 1 Global Osteoporosis Drugs Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
  • Table 4 Global Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
  • Table 5 Global Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
  • Table 6 Global Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
  • Table 7 Global Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
  • Table 8 Global Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
  • Table 9 Global Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
  • Table 10 Global Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
  • Table 11 Global Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 12 Global Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 13 Global Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 14 Global Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 15 Global Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 16 Global Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 17 Global Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 18 Global Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 19 Global Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 20 Global Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 21 Global Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 22 Global Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 23 North America Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
  • Table 24 North America Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 25 North America Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
  • Table 26 North America Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
  • Table 27 North America Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
  • Table 28 North America Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
  • Table 29 North America Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
  • Table 30 North America Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
  • Table 31 North America Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
  • Table 32 North America Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
  • Table 33 North America Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 34 North America Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 35 North America Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 36 North America Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 37 North America Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 38 North America Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 39 North America Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 40 North America Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 41 North America Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 42 North America Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 43 North America Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 44 North America Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 45 Europe Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
  • Table 46 Europe Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 47 Europe Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
  • Table 48 Europe Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
  • Table 49 Europe Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
  • Table 50 Europe Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
  • Table 51 Europe Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
  • Table 52 Europe Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
  • Table 53 Europe Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
  • Table 54 Europe Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
  • Table 55 Europe Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 56 Europe Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 57 Europe Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 58 Europe Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 59 Europe Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 60 Europe Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 61 Europe Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 62 Europe Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 63 Europe Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 64 Europe Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 65 Europe Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 66 Europe Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 67 Asia Pacific Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
  • Table 68 Asia Pacific Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 69 Asia Pacific Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
  • Table 70 Asia Pacific Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
  • Table 71 Asia Pacific Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
  • Table 72 Asia Pacific Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
  • Table 73 Asia Pacific Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
  • Table 74 Asia Pacific Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
  • Table 75 Asia Pacific Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
  • Table 76 Asia Pacific Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
  • Table 77 Asia Pacific Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 78 Asia Pacific Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 79 Asia Pacific Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 80 Asia Pacific Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 81 Asia Pacific Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 82 Asia Pacific Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 83 Asia Pacific Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 84 Asia Pacific Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 85 Asia Pacific Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 86 Asia Pacific Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 87 Asia Pacific Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 88 Asia Pacific Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 89 South America Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
  • Table 90 South America Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 91 South America Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
  • Table 92 South America Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
  • Table 93 South America Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
  • Table 94 South America Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
  • Table 95 South America Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
  • Table 96 South America Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
  • Table 97 South America Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
  • Table 98 South America Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
  • Table 99 South America Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 100 South America Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 101 South America Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 102 South America Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 103 South America Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 104 South America Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 105 South America Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 106 South America Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 107 South America Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 108 South America Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 109 South America Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 110 South America Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 111 Middle East & Africa Osteoporosis Drugs Market Outlook, By Country (2024-2032) ($MN)
  • Table 112 Middle East & Africa Osteoporosis Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 113 Middle East & Africa Osteoporosis Drugs Market Outlook, By Bisphosphonates (2024-2032) ($MN)
  • Table 114 Middle East & Africa Osteoporosis Drugs Market Outlook, By Alendronate (2024-2032) ($MN)
  • Table 115 Middle East & Africa Osteoporosis Drugs Market Outlook, By Risedronate (2024-2032) ($MN)
  • Table 116 Middle East & Africa Osteoporosis Drugs Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2024-2032) ($MN)
  • Table 117 Middle East & Africa Osteoporosis Drugs Market Outlook, By Parathyroid Hormone-Related Protein (PTHrP) Analogues (2024-2032) ($MN)
  • Table 118 Middle East & Africa Osteoporosis Drugs Market Outlook, By Parathyroid Hormone (PTH) Analogs (2024-2032) ($MN)
  • Table 119 Middle East & Africa Osteoporosis Drugs Market Outlook, By RANK Ligand (RANKL) Inhibitors (2024-2032) ($MN)
  • Table 120 Middle East & Africa Osteoporosis Drugs Market Outlook, By Calcitonin (2024-2032) ($MN)
  • Table 121 Middle East & Africa Osteoporosis Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 122 Middle East & Africa Osteoporosis Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 123 Middle East & Africa Osteoporosis Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 124 Middle East & Africa Osteoporosis Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 125 Middle East & Africa Osteoporosis Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 126 Middle East & Africa Osteoporosis Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 127 Middle East & Africa Osteoporosis Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 128 Middle East & Africa Osteoporosis Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 129 Middle East & Africa Osteoporosis Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 130 Middle East & Africa Osteoporosis Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 131 Middle East & Africa Osteoporosis Drugs Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 132 Middle East & Africa Osteoporosis Drugs Market Outlook, By Homecare Settings (2024-2032) ($MN)